Does the media prefer RNA or ACRS?

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 2 mentions for Avidity Biosciences. Aclaris Therapeutics' average media sentiment score of 1.16 beat Avidity Biosciences' score of 0.62 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DSGN or RNA?

In the previous week, Design Therapeutics had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 4 mentions for Design Therapeutics and 2 mentions for Avidity Biosciences. Design Therapeutics' average media sentiment score of 1.02 beat Avidity Biosciences' score of 0.62 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RNA or ZVRA?

In the previous week, Zevra Therapeutics had 15 more articles in the media than Avidity Biosciences. MarketBeat recorded 17 mentions for Zevra Therapeutics and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.62 beat Zevra Therapeutics' score of 0.25 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer RNA or CADL?

In the previous week, Avidity Biosciences and Avidity Biosciences both had 2 articles in the media. Candel Therapeutics' average media sentiment score of 0.96 beat Avidity Biosciences' score of 0.62 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNPR or RNA?

In the previous week, Monopar Therapeutics had 14 more articles in the media than Avidity Biosciences. MarketBeat recorded 16 mentions for Monopar Therapeutics and 2 mentions for Avidity Biosciences. Monopar Therapeutics' average media sentiment score of 0.87 beat Avidity Biosciences' score of 0.62 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avidity Biosciences (RNA) Competitors

$11.55 -0.02 (-0.17%)

As of 01:45 PM Eastern

Compare

RNA vs. ACRS, DSGN, ZVRA, CADL, and MNPR

Should you buy Avidity Biosciences stock or one of its competitors? MarketBeat compares Avidity Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avidity Biosciences include Aclaris Therapeutics (ACRS), Design Therapeutics (DSGN), Zevra Therapeutics (ZVRA), Candel Therapeutics (CADL), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry.

How does Avidity Biosciences compare to Aclaris Therapeutics?

Avidity Biosciences (NASDAQ:RNA) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 2 mentions for Avidity Biosciences. Aclaris Therapeutics' average media sentiment score of 1.16 beat Avidity Biosciences' score of 0.62 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avidity Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Aclaris Therapeutics has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.39	-$322.30M	-$0.97	N/A
Aclaris Therapeutics	$7.83M	94.27	-$64.92M	-$0.56	N/A

98.3% of Aclaris Therapeutics shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Avidity Biosciences presently has a consensus price target of $67.60, suggesting a potential upside of 485.28%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 117.60%. Given Avidity Biosciences' higher probable upside, equities research analysts clearly believe Avidity Biosciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Aclaris Therapeutics has a net margin of -832.58% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Summary

Aclaris Therapeutics beats Avidity Biosciences on 11 of the 16 factors compared between the two stocks.

How does Avidity Biosciences compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Design Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Avidity Biosciences	$36.68M	5.39	-$322.30M	-$0.97	N/A

Design Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 39.59%. Avidity Biosciences has a consensus price target of $67.60, suggesting a potential upside of 485.28%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28

Design Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Design Therapeutics' return on equity of -33.07% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

In the previous week, Design Therapeutics had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 4 mentions for Design Therapeutics and 2 mentions for Avidity Biosciences. Design Therapeutics' average media sentiment score of 1.02 beat Avidity Biosciences' score of 0.62 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.6% of Design Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Design Therapeutics beats Avidity Biosciences on 11 of the 15 factors compared between the two stocks.

How does Avidity Biosciences compare to Zevra Therapeutics?

Avidity Biosciences (NASDAQ:RNA) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Avidity Biosciences presently has a consensus price target of $67.60, indicating a potential upside of 485.28%. Zevra Therapeutics has a consensus price target of $26.86, indicating a potential upside of 179.47%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Zevra Therapeutics has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.39	-$322.30M	-$0.97	N/A
Zevra Therapeutics	$122.29M	4.65	$83.23M	$1.99	4.83

Avidity Biosciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

35.0% of Zevra Therapeutics shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Zevra Therapeutics has a net margin of 101.58% compared to Avidity Biosciences' net margin of -3,650.39%. Zevra Therapeutics' return on equity of 51.49% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Zevra Therapeutics	101.58%	51.49%	28.86%

In the previous week, Zevra Therapeutics had 15 more articles in the media than Avidity Biosciences. MarketBeat recorded 17 mentions for Zevra Therapeutics and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.62 beat Zevra Therapeutics' score of 0.25 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Zevra Therapeutics beats Avidity Biosciences on 11 of the 17 factors compared between the two stocks.

How does Avidity Biosciences compare to Candel Therapeutics?

Avidity Biosciences (NASDAQ:RNA) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

13.9% of Candel Therapeutics shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Avidity Biosciences currently has a consensus target price of $67.60, indicating a potential upside of 485.28%. Candel Therapeutics has a consensus target price of $18.57, indicating a potential upside of 89.41%. Given Avidity Biosciences' higher probable upside, equities analysts clearly believe Avidity Biosciences is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Avidity Biosciences and Avidity Biosciences both had 2 articles in the media. Candel Therapeutics' average media sentiment score of 0.96 beat Avidity Biosciences' score of 0.62 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Candel Therapeutics	N/A	-60.42%	-41.33%

Candel Therapeutics has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.39	-$322.30M	-$0.97	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Avidity Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, meaning that its stock price is 152% less volatile than the broader market.

Summary

Avidity Biosciences beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Avidity Biosciences compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, Monopar Therapeutics had 14 more articles in the media than Avidity Biosciences. MarketBeat recorded 16 mentions for Monopar Therapeutics and 2 mentions for Avidity Biosciences. Monopar Therapeutics' average media sentiment score of 0.87 beat Avidity Biosciences' score of 0.62 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Monopar Therapeutics' return on equity of -12.84% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Monopar Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Avidity Biosciences	$36.68M	5.39	-$322.30M	-$0.97	N/A

Monopar Therapeutics presently has a consensus price target of $112.08, suggesting a potential upside of 3.03%. Avidity Biosciences has a consensus price target of $67.60, suggesting a potential upside of 485.28%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28

Monopar Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

1.8% of Monopar Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Monopar Therapeutics beats Avidity Biosciences on 12 of the 16 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNA vs. The Competition

Export

Metric	Avidity Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$197.57M	$3.71B	$7.04B	$12.15B
Dividend Yield	N/A	2.18%	2.67%	9.43%
P/E Ratio	-2.32	21.93	27.27	23.75
Price / Sales	5.39	167.62	491.52	73.76
Price / Cash	N/A	59.51	26.39	46.67
Price / Book	1.06	7.92	10.24	6.10
Net Income	-$322.30M	$23.81M	$3.60B	$331.80M
7 Day Performance	-6.02%	-4.35%	-1.93%	-2.13%
1 Month Performance	-12.43%	-5.02%	-2.83%	-3.30%
1 Year Performance	-66.58%	31.85%	17.80%	13.44%

Avidity Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNA Avidity Biosciences	2.3679 of 5 stars	$11.55 -0.2%	$67.60 +485.3%	-68.1%	$197.57M	$36.68M	N/A	190
ACRS Aclaris Therapeutics	3.0098 of 5 stars	$5.57 -1.9%	$11.50 +106.5%	+215.9%	$793.29M	$7.83M	N/A	100	Positive News
DSGN Design Therapeutics	2.9088 of 5 stars	$11.87 -5.6%	$16.50 +39.0%	+195.5%	$785.08M	N/A	N/A	40	News Coverage
ZVRA Zevra Therapeutics	4.3373 of 5 stars	$12.03 -5.8%	$29.29 +143.4%	-13.5%	$754.90M	$106.47M	6.05	20	News Coverage Analyst Forecast
CADL Candel Therapeutics	2.5209 of 5 stars	$9.57 -6.0%	$18.57 +94.1%	+41.9%	$745.89M	N/A	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNA) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Competitors

RNA vs. ACRS, DSGN, ZVRA, CADL, and MNPR

How does Avidity Biosciences compare to Aclaris Therapeutics?

Summary

How does Avidity Biosciences compare to Design Therapeutics?

Summary

How does Avidity Biosciences compare to Zevra Therapeutics?

Summary

How does Avidity Biosciences compare to Candel Therapeutics?

Summary

How does Avidity Biosciences compare to Monopar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avidity Biosciences (RNA) Competitors

RNA vs. ACRS, DSGN, ZVRA, CADL, and MNPR

How does Avidity Biosciences compare to Aclaris Therapeutics?

Does the media prefer RNA or ACRS?

Which has more volatility & risk, RNA or ACRS?

Which has higher earnings & valuation, RNA or ACRS?

Do institutionals and insiders have more ownership in RNA or ACRS?

Do analysts rate RNA or ACRS?

Is RNA or ACRS more profitable?

Summary

How does Avidity Biosciences compare to Design Therapeutics?

Which has higher valuation and earnings, DSGN or RNA?

Which has more volatility and risk, DSGN or RNA?

Do analysts recommend DSGN or RNA?

Is DSGN or RNA more profitable?

Does the media refer more to DSGN or RNA?

Do insiders & institutionals hold more shares of DSGN or RNA?

Summary

How does Avidity Biosciences compare to Zevra Therapeutics?

Do analysts prefer RNA or ZVRA?

Which has better earnings & valuation, RNA or ZVRA?

Which has more risk & volatility, RNA or ZVRA?

Do institutionals & insiders believe in RNA or ZVRA?

Is RNA or ZVRA more profitable?

Does the media prefer RNA or ZVRA?

Summary

How does Avidity Biosciences compare to Candel Therapeutics?

Do insiders & institutionals believe in RNA or CADL?

Do analysts rate RNA or CADL?

Does the media prefer RNA or CADL?

Is RNA or CADL more profitable?

Which has higher valuation & earnings, RNA or CADL?

Which has more volatility & risk, RNA or CADL?

Summary

How does Avidity Biosciences compare to Monopar Therapeutics?

Does the media refer more to MNPR or RNA?

Is MNPR or RNA more profitable?

Which has better earnings & valuation, MNPR or RNA?

Do analysts rate MNPR or RNA?

Which has more volatility & risk, MNPR or RNA?

Do institutionals and insiders hold more shares of MNPR or RNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools